MANNKIND CORP (MNKD) Fundamental Analysis & Valuation

NASDAQ:MNKD • US56400P7069

2.61 USD
-0.07 (-2.61%)
At close: Mar 10, 2026
2.75 USD
+0.14 (+5.36%)
Pre-Market: 3/11/2026, 8:22:03 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 519 industry peers in the Biotechnology industry. There are concerns on the financial health of MNKD while its profitability can be described as average. MNKD has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

6

1. MNKD Profitability Analysis

1.1 Basic Checks

  • In the past year MNKD was profitable.
  • MNKD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MNKD reported negative net income in multiple years.
  • In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • The Return On Assets of MNKD (0.85%) is better than 88.05% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.96%, MNKD belongs to the top of the industry, outperforming 92.68% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for MNKD is significantly below the industry average of 19.44%.
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROIC 7.96%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100 -150

1.3 Margins

  • MNKD's Profit Margin of 1.92% is amongst the best of the industry. MNKD outperforms 88.25% of its industry peers.
  • Looking at the Operating Margin, with a value of 16.59%, MNKD belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 77.80%, MNKD belongs to the top of the industry, outperforming 84.20% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MNKD has grown nicely.
Industry RankSector Rank
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MNKD Health Analysis

2.1 Basic Checks

  • MNKD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for MNKD has been increased compared to 1 year ago.
  • The number of shares outstanding for MNKD has been increased compared to 5 years ago.
  • MNKD has a worse debt/assets ratio than last year.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -4.21, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
  • MNKD has a Altman-Z score of -4.21. This is in the lower half of the industry: MNKD underperforms 60.50% of its industry peers.
  • The Debt to FCF ratio of MNKD is 44.51, which is on the high side as it means it would take MNKD, 44.51 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 44.51, MNKD belongs to the best of the industry, outperforming 89.98% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Altman-Z -4.21
ROIC/WACC0.99
WACC8.07%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 1.70 indicates that MNKD should not have too much problems paying its short term obligations.
  • MNKD has a worse Current ratio (1.70) than 79.38% of its industry peers.
  • A Quick Ratio of 1.50 indicates that MNKD should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.50, MNKD is not doing good in the industry: 80.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.5
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MNKD Growth Analysis

3.1 Past

  • The earnings per share for MNKD have decreased strongly by -28.75% in the last year.
  • Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 22.23%.
  • Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 39.91% on average per year.
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%

3.2 Future

  • The Earnings Per Share is expected to grow by 52.44% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.70% on average over the next years. This is quite good.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year34.43%
Revenue Next 2Y25.13%
Revenue Next 3Y18.13%
Revenue Next 5Y17.7%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. MNKD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 43.50, which means the current valuation is very expensive for MNKD.
  • Based on the Price/Earnings ratio, MNKD is valued cheaply inside the industry as 90.37% of the companies are valued more expensively.
  • MNKD is valuated expensively when we compare the Price/Earnings ratio to 26.25, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 49.00, MNKD can be considered very expensive at the moment.
  • MNKD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 90.56% of the companies in the same industry.
  • MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.39.
Industry RankSector Rank
PE 43.5
Fwd PE 49
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 94.61% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 58.74
EV/EBITDA 15.81
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The decent profitability rating of MNKD may justify a higher PE ratio.
  • MNKD's earnings are expected to grow with 65.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MNKD Dividend Analysis

5.1 Amount

  • No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MNKD Fundamentals: All Metrics, Ratios and Statistics

MANNKIND CORP

NASDAQ:MNKD (3/10/2026, 8:00:01 PM)

Premarket: 2.75 +0.14 (+5.36%)

2.61

-0.07 (-2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners58.06%
Inst Owner Change3.5%
Ins Owners1.57%
Ins Owner Change1.58%
Market Cap804.14M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts85.33
Price Target9.8 (275.48%)
Short Float %8.8%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-33.3%
EPS NQ rev (3m)0%
EPS NY rev (1m)-38.97%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)7.18%
Revenue NQ rev (3m)9.23%
Revenue NY rev (1m)7.09%
Revenue NY rev (3m)9.77%
Valuation
Industry RankSector Rank
PE 43.5
Fwd PE 49
P/S 2.3
P/FCF 58.74
P/OCF 44.05
P/B N/A
P/tB N/A
EV/EBITDA 15.81
EPS(TTM)0.06
EY2.3%
EPS(NY)0.05
Fwd EY2.04%
FCF(TTM)0.04
FCFY1.7%
OCF(TTM)0.06
OCFY2.27%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROCE 9.32%
ROIC 7.96%
ROICexc 10.76%
ROICexgc 55.79%
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
FCFM 3.92%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Debt/EBITDA 8.33
Cap/Depr 37.17%
Cap/Sales 1.31%
Interest Coverage 3.93
Cash Conversion 26.02%
Profit Quality 204.41%
Current Ratio 1.7
Quick Ratio 1.5
Altman-Z -4.21
F-Score5
WACC8.07%
ROIC/WACC0.99
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year34.43%
Revenue Next 2Y25.13%
Revenue Next 3Y18.13%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


Can you provide the profitability details for MANNKIND CORP?

MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?

The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 43.5 and the Price/Book (PB) ratio is -15.76.